Novartis AG (NVS) to Add Warnings to Rasilez Blood-Pressure Drug  
2/17/2012 7:23:41 AM

Novartis AG (NOVN) said it will add a warning to the label for its blood-pressure drug Rasilez in Europe to comply with a request from regulators. Novartis is changing the product information for Rasilez, sold in the U.S. as Tekturna, to say that the drug should not be used to treat patients with diabetes or kidney problems who are taking certain other medicines, the Basel, Switzerland-based company said in a statement today.The drugmaker is also complying with a recommendation of the European Medicines Agency that the label include a warning against combining products containing aliskiren, the active ingredient in Rasilez, with heart drugs known as ACE inhibitors or ARBs, the agency said today in an e-mailed statement. Novartis halted a trial of the drug in December after it was linked to increased risk of stroke and kidney problems.